Analysts Offer Insights on Healthcare Companies: Trevena Inc (NASDAQ: TRVN), Seres Therapeutics (NASDAQ: MCRB) and BioDelivery (NASDAQ: BDSI)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trevena Inc (NASDAQ: TRVN), Seres Therapeutics (NASDAQ: MCRB) and BioDelivery (NASDAQ: BDSI) with bullish sentiments.

Trevena Inc (NASDAQ: TRVN)

Oppenheimer analyst Derek Archila assigned a Buy rating to Trevena Inc (NASDAQ: TRVN) today and set a price target of $5. The company’s shares opened today at $2, close to its 52-week low of $1.84.

Archila noted:

“TRVN announced its will be initiating a restructuring plan which will largely eliminate its R&D function. We believe this is a smart move for TRVN as it needs to conserve cash for a 2H18 Olinvo approval/launch. We believe investors gave TRVN modest credit for its early pipeline and with the cutback on R&D, it is now unlikely the pipeline will yield a monetizable program. Our overall thesis, that Olinvo (post-surgical pain) will find its niche as a treatment for patients at high risk of opioid related AEs, does not change and think today’s -15% stock move is likely overdone.”

According to TipRanks.com, Archila is ranked 0 out of 5 stars with an average return of -12.5% and a 32.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Zynerba Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Trevena Inc is Strong Buy and the average price target is $7.63, representing a 281.5% upside.

In a report released today, H.C. Wainwright also assigned a Buy rating to the stock with a $7 price target.
Seres Therapeutics (NASDAQ: MCRB)

Seres Therapeutics (NASDAQ: MCRB) received a Buy rating and a $19 price target from Oppenheimer analyst Mark Breidenbach today. The company’s shares opened today at $11.01.

Breidenbach observed:

“Seres Therapeutics is a leader in development of microbial therapeutics for treatment of infectious and inflammatory diseases. The company’s therapeutic pipeline is based on the premise that the composition of the gut microbiome can have positive or negative consequences on human health. Seres is an innovator operating at the forefront of scientific discovery, which has contributed to some setbacks in product development. However, we believe the company’s pivotal ECOSPOR III trial of SER-109 is thoughtfully designed to avoid the shortcomings from the drug’s Phase 2 experience. Additionally, Seres recently reported compelling top-line data in ulcerative colitis (UC) which could reinvigorate investor interest in microbiome medicine.”

According to TipRanks.com, Breidenbach is a 3-star analyst with an average return of 5.2% and a 43.8% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Global Blood Therapeutics, and RXi Pharmaceuticals Corp.

Currently, the analyst consensus on Seres Therapeutics is Strong Buy and the average price target is $18.50, representing a 68.0% upside.

In a report issued on October 2, Cantor Fitzgerald also assigned a Buy rating to the stock with a $16 price target.
BioDelivery (NASDAQ: BDSI)

Roth Capital analyst Scott Henry reiterated a Buy rating on BioDelivery (NASDAQ: BDSI) today and set a price target of $5. The company’s shares opened today at $3.

According to TipRanks.com, Henry is a 4-star analyst with an average return of 3.9% and a 47.0% success rate. Henry covers the Healthcare sector, focusing on stocks such as Acerus Pharmaceuticals Corporation, Synergy Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.

Currently, the analyst consensus on BioDelivery is Strong Buy and the average price target is $4.50, representing a 50.0% upside.

In a report released today, Cantor Fitzgerald also assigned a Buy rating to the stock with a $4.50 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.